Strategies for COVID-19 vaccination under a shortage scenario: a geo-stochastic modelling approach

In a world being hit by waves of COVID-19, vaccination is a light on the horizon. However, the roll-out of vaccination strategies and their influence on the pandemic are still open problems. In order to compare the effect of various strategies proposed by the World Health Organization and other authorities, a previously developed SEIRS stochastic model of geographical spreading of the virus is extended by adding a compartment for vaccinated people. The parameters of the model were fitted to describe the pandemic evolution in Argentina, Mexico and Spain to analyze the effect of the proposed vaccination strategies. The mobility parameters allow to simulate different social behaviors (e.g. lock-down interventions). Schemes in which vaccines are applied homogeneously in all the country, or limited to the most densely-populated areas, are simulated and compared. The second strategy is found to be more effective. Moreover, under the current global shortage of vaccines, it should be remarked that immunization is enhanced when mobility is reduced. Additionally, repetition of vaccination campaigns should be timed considering the immunity lapse of the vaccinated (and recovered) people. Finally, the model is extended to include the effect of isolation of detected positive cases, shown to be important to reduce infections.

[1]  Selva Demiralp,et al.  The Economic Case for Global Vaccinations: An Epidemiological Model with International Production Networks , 2021 .

[2]  A. Rinaldo,et al.  Spread and dynamics of the COVID-19 epidemic in Italy: Effects of emergency containment measures , 2020, Proceedings of the National Academy of Sciences.

[3]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[4]  A. Gamarnik,et al.  Community-level SARS-CoV-2 Seroprevalence Survey in urban slum dwellers of Buenos Aires City, Argentina: a participatory research. , 2020, medRxiv.

[5]  R. Barrio,et al.  Detecting infected asymptomatic cases in a stochastic model for spread of Covid-19: the case of Argentina , 2020, Scientific Reports.

[6]  A. Flahault,et al.  Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study , 2020, The Lancet.

[7]  L. Matrajt,et al.  Vaccine optimization for COVID-19: who to vaccinate first? , 2020, Science Advances.

[8]  E. Segal,et al.  Longitudinal symptom dynamics of COVID-19 infection , 2020, Nature Communications.

[9]  G. Yamey Rich countries should tithe their vaccines , 2021, Nature.

[10]  M. Keeling,et al.  Efficacy of contact tracing for the containment of the 2019 novel coronavirus (COVID-19) , 2020, Journal of Epidemiology & Community Health.

[11]  Christophe Fraser,et al.  The Effectiveness of Contact Tracing in Emerging Epidemics , 2006, PloS one.

[12]  E. Dong,et al.  An interactive web-based dashboard to track COVID-19 in real time , 2020, The Lancet Infectious Diseases.

[13]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[14]  C. Aschwanden The false promise of herd immunity for COVID-19 , 2020, Nature.

[15]  Jessica T Davis,et al.  Estimating the effect of cooperative versus uncooperative strategies of COVID-19 vaccine allocation: a modeling study , 2020 .

[16]  M. Jit,et al.  Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment , 2021, The Lancet.

[17]  S. Straus,et al.  The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines , 2021, The Lancet.

[18]  T. Hale,et al.  Oxford COVID-19 Government Response Tracker , 2020 .

[19]  Tzipe Govezensky,et al.  A Discrete SEIRS Model for Pandemic Periodic Infectious Diseases , 2012 .

[20]  Eric J Topol,et al.  Prevalence of Asymptomatic SARS-CoV-2 Infection , 2020, Annals of Internal Medicine.

[21]  K. Jarrod Millman,et al.  Array programming with NumPy , 2020, Nat..

[22]  E. Emanuel,et al.  An ethical framework for global vaccine allocation , 2020, Science.

[23]  Anya Göpfert,et al.  Accelerating global vaccination coverage of frontline workers and populations at risk of severe COVID-19 complications , 2021, Public Health.

[24]  P. Klepac,et al.  Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts , 2020, The Lancet Global Health.

[25]  M. Hernán,et al.  Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study , 2020, The Lancet.

[26]  Royce J. Wilson,et al.  Google COVID-19 Community Mobility Reports: Anonymization Process Description (version 1.0) , 2020, ArXiv.

[27]  K. Kaski,et al.  Modelling Covid-19 epidemic in Mexico, Finland and Iceland , 2020, 2007.10806.

[28]  Guillermo Soberon,et al.  The case of Mexico , 1992 .

[29]  Andrea Cornwall,et al.  What is participatory research? , 1995, Social science & medicine.

[30]  J. Lessler,et al.  Estimating the burden of SARS-CoV-2 in France , 2020, Science.

[31]  C. Fraser,et al.  Factors that make an infectious disease outbreak controllable. , 2004, Proceedings of the National Academy of Sciences of the United States of America.